Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.

被引：0
|
作者：
Drilon, Alexander E.
Kummar, Shivaani
Lin, Jessica Jiyeong
Tan, Daniel Shao-Weng
Moreno, Victor
Leyvraz, Serge
Dubashi, Biswajit
Haresh, K. P.
Burcoveanu, Domnita-Ileana
Neu, Natascha
Mussi, Chiara E.
Shen, Lin
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[5] Harvard Med Sch, Boston, MA USA
[6] Duke NUS Med Sch, Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[7] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain
[8] Charit Univ Med Berlin, Berlin, Germany
[9] Jawaharlal Inst Postgrade Med Educ & Res, Pondicherry, India
[10] All India Inst Med Sci AIIMS, New Delhi, India
[11] Bayer HealthCare Pharmaceut Inc, Basel, Switzerland
[12] Chrestos Concept GmbH & Co KG, Essen, Germany
[13] Bayer SpA, Milan, Italy
[14] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing Key Lab Carcinogenesis & Translat Res, State Key Lab Holist Integrat Management Gastroin, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8570
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Larotrectinib Demonstrates Durable Efficacy and Safety in an Expanded Dataset of Pediatric Patients with TRK Fusion Cancer
    Koga, Yuhki
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [42] Larotrectinib Demonstrates Durable Efficacy and Safety in an Expanded Dataset Of Pediatric Patients With TRK Fusion Cancer
    Mascarenhas, L.
    Albert, C.
    Pappo, A.
    Geoerger, B.
    Doz, F.
    Federman, N.
    Nagasubramanian, R.
    Bielack, S.
    Dubois, S.
    Morgenstern, D.
    Schulte, J.
    Shukla, N.
    Reeves, J.
    De La Cuesta, E.
    Dima, L.
    Childs, B.
    Laetsch, T.
    Van Tilburg, C. M.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S51 - S51
  • [43] Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib
    Hoejgaard, M.
    Drilon, A.
    Lin, J. J.
    Kummar, S.
    Tan, D. S. W.
    Patel, J.
    Leyvraz, S.
    Garcia, V. Moreno
    Rosen, L. S.
    Solomon, B.
    Yachnin, J.
    Liu, Y.
    Dai, M-S.
    Norenberg, R.
    Burcoveanu, D-I.
    Yun, L.
    Beckmann, G.
    Mussi, C. E.
    Shen, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S48 - S49
  • [44] Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
    Hong, D. S.
    Tahara, M.
    Baik, C.
    Bauman, J. R.
    Gilbert, J.
    Brose, M. S.
    Grilley-Olson, J. E.
    Patil, T.
    McDermott, R.
    Raez, L. E.
    Johnson, J. M.
    Shen, L.
    Norenberg, R.
    Dima, L.
    Mussi, C.
    Le, X.
    Drilon, A. E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S847 - S848
  • [45] Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
    Shen, L.
    Hong, D. S.
    Tahara, M.
    Baik, C. S.
    Bauman, J. R.
    Gilbert, J.
    Brose, M. S.
    Grilley-Olson, J. E.
    Patil, T.
    McDermott, R. S.
    Raez, L. E.
    Johnson, J. M.
    Norenberg, R.
    Dima, L.
    Mussi, C. E.
    Le, X.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S1521 - S1522
  • [46] Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
    Waguespack, Steven G.
    Drilon, Alexander
    Lin, Jessica J.
    Brose, Marcia S.
    McDermott, Ray
    Almubarak, Mohammed
    Bauman, Jessica
    Casanova, Michela
    Krishnamurthy, Anuradha
    Kummar, Shivaani
    Leyvraz, Serge
    Oh, Do-Youn
    Park, Keunchil
    Sohal, Davendra
    Sherman, Eric
    Norenberg, Ricarda
    Silvertown, Josh D.
    Brega, Nicoletta
    Hong, David S.
    Cabanillas, Maria E.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 186 (06) : 631 - 643
  • [47] Efficacy of larotrectinib in TRK fusion cancer in adults and children
    Blattmann, C.
    Drilon, A.
    Laetsch, T. W.
    Kummar, S.
    DuBois, S. G.
    Lassen, U. N.
    Demetri, G. D.
    Nathenson, M.
    Doebele, R. C.
    Farago, A. F.
    Pappo, A. S.
    Turpin, B.
    Dowlati, A.
    Brose, M. S.
    Mascarenhas, L.
    Federman, N.
    Berlin, J.
    El-Deiry, W. S.
    Baik, C.
    Deeken, J.
    Boni, V.
    Nagasubramanian, R.
    Taylor, M.
    Rudzinski, E. R.
    Meric-Bernstam, F.
    Sohal, D. P. S.
    Ma, P. C.
    Raez, L. E.
    Hechtman, J. F.
    Benayed, R.
    Ladanyi, M.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Hawkins, D. S.
    Hong, D. S.
    Hyman, D. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 154 - 155
  • [48] Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Drilon, A.
    Shen, L.
    van Tilburg, C.
    Doz, F.
    Tan, D. S. W.
    Lin, J. J.
    Kummar, S.
    Lassen, U. N.
    McDermott, R. S.
    Dierselhuis, M. P.
    Albert, C. M.
    Nagasubramanian, R.
    Watt, T.
    Patil, T.
    Burcoveanu, D-I.
    Norenberg, R.
    Brega, N.
    Laetsch, T. W.
    Xu, R-H.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S470 - S470
  • [49] LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMOURS
    Nysom, Karsten
    Doz, Francois
    Geoerger, Birgit
    Ora, Ingrid
    Perreault, Sebastien
    Norenberg, Ricarda
    Fellous, Marc
    De La Cuesta, Esther
    Laetsch, Theodore W.
    van Tilburg, Cornelis M.
    NEURO-ONCOLOGY, 2022, 24 : 64 - 64
  • [50] The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer
    Suh, Kangho
    Carlson, Josh John
    Xia, Fang
    Williamson, Todd E.
    Sullivan, Sean D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345